medigraphic.com

2013, Número 3

<< Anterior Siguiente >>

Rev Hematol Mex 2013; 14 (3)


Enfermedad de injerto contra huésped pulmonar crónica postrasplante de células hematopoyéticas alogénicas. Aspectos diagnósticos y terapéuticos

Fernández-Lara D, Domínguez-Cid M, Ruiz-Delgado GJ

Idioma: Español
Referencias bibliográficas: 67
Paginas: 138-144
Archivo PDF: 287.81 Kb.


RESUMEN

La enfermedad de injerto contra huésped crónica es una complicación frecuente de los pacientes que reciben trasplante alogénico de células hematopoyéticas. Las complicaciones pulmonares de la enfermedad de injerto contra huésped crónica implican una morbilidad y mortalidad elevadas. Estas complicaciones pueden manifestarse de diversas maneras y sus patrones y esquemas de tratamiento son característicos. El diagnóstico y tratamiento oportunos contribuyen a la mejoría clínica de los pacientes con esta complicación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant 2010; 45: 295-302.

  2. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784-3792.

  3. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the international bone marrow transplant registry and the European group for blood and marrow transplantation. Blood 2006; 108: 4288- 4290.

  4. Cooke KR, Hildebrandt GC. Pulmonary toxicity following hematopoietic cell transplantation: is the lung a target organ of graft-versus-host disease? Curr Opin Organ Transplant 2006; 11: 69-77.

  5. Tichelli A, Rovo A, Gratwohl A. Late pulmonary, cardiovascular, and renal complications after hemato-poietic stem cell transplantation and recommended screening practices. Hematology Am Soc Hematol Educ Program 2008;125-133.

  6. Bolanos-Meade J, Chien J. Chronic graft versus host disease and the lung. In: Vogelsang, GB and Pavletic, SZ (eds). Chronic Graft Versus Host Disease: Interdisciplinary Management. Cambridge: Cambridge University Press, 2009; 37.

  7. Patriarca F, Skert C, Sperotto A, Damiani D, Cerno M, Geromin A, et al. Incidence, outcome, and risk factors of lateonset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004; 33: 751-758.

  8. Sakaida E, Nakaseko C, Harima A, Yokota A, Cho R, Saito Y, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003; 102: 4236-4242.

  9. Savani BN, Montero A, Srinivasan R, Singh A, Shenoy A, Mielke S, et al. Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 1261-1269.

  10. Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M, et al. Late-onset non-infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in children. Bone Marrow Transplant 2009; 44: 303-308.

  11. Freudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Blood 2003; 102: 3822-3828.

  12. Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant 2007; 39: 667-675.

  13. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.

  14. Clark JG, Crawford SW, Madtes DK, Sullivan KM. Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course. Ann Intern Med 1989; 111: 368-376.

  15. Sullivan K, Mori M, Sanders J, Siadak M, Witherspoon RP, Anasetti C , et al. Late complications of allogeneic and autologous bone marrow transplantation. Bone Marrow Transplant 1992; 10: 127-134.

  16. Sanchez J, Torres A, Serrano J, Romain J, Martin C, Perula L , et al. Long term follow up of immu-nosuppressive treatment for obstructive airway disease after allogeneic bone marrow trans-plantation. Bone Marrow Transplant 1997; 20: 403-408.

  17. Badier M, Guillot C, Delpierre S, Vanuxem P, Blaise D, Maraninchi D. Pulmonary function changes 100 days and one year after bone marrow transplantation. Bone Marrow Transplant 1993; 12: 457-461.

  18. Crawford SW, Pepe M, Lin D, Benedetti F, Deeg HJ. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med 1995; 152: 690-695.

  19. Watkins TR, Chien JW, Crawford SW. Graft versus hostassociated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Semin Respir Crit Care Med 2005; 26: 482-489.

  20. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR, Nichols WG, et al. Airflow obstruction after myeloablative allo geneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003; 168: 208-214.

  21. Afessa B, Litzow MR, Tefferi A. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 425-434.

  22. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG. Blood 1988; 72: 621-627.

  23. Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG, et al. Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998; 100: 680-687.

  24. Duncker C, Dohr D, Harsdorf S, Duyster J, Stefanic M, Martini C, et al. Non-infectious lung complications are closely associated with chronic graft-versus-host disease: a single center study of incidence, risk factors and outcome. Bone Marrow Transplant 2000; 25: 1263-1268.

  25. Marras TK, Chan CK, Lipton JH, Messner HA, Szalai JP, Laupacis A. Long-term pulmonary function abnormalities and survival after allogeneic marrow transplantation. Bone Marrow Transplant 2004; 33: 509-517.

  26. Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004; 77: 1096-1100.

  27. Chien JW, Madtes DK, Clark JG. Pulmonary function testing prior to hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35: 429-435.

  28. Walter EC, Orozco-Levi M, Ramirez-Sarmiento A, Vigorito A, Campregher PV, Martin PJ, et al. Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant 2010; 16: 53-61.

  29. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 2006; 12: 375-396.

  30. Rabanus R, Hahn J, Andreesen R, Holler E, Hildebrandt GC. Risk factor analysis for the development of restrictive and obstructive pulmonary function changes after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 2008; 14: S6.

  31. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968.

  32. Escuissato DL, Gasparetto EL, Marchiori E, Rocha Gde M, Inoue C, Pasquini R, et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol 2005; 185: 608-615.

  33. Chamberlain D, Maurer J, Chaparro C, Idolor L. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1994; 13: 963-971.

  34. Hayes-Jordan A, Benaim E, Richardson S, Joglar J, Srivastava DK, Bowman L, et al. Open lung biopsy in pediatric bone marrow transplant patients. J Pediatr Surg 2002; 37: 446-452.

  35. Bergeron A, Belle A, Chevret S, Ribaud P, Devergie A, Esperou H, et al. Combined inhaled steroids and bronchodilatators in obstructive airway disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39:547-553.

  36. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA, et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 63-67.

  37. Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001; 103: 544-548.

  38. Ivy DD, Doran AK, Smith KJ, Mallory Jr GB, Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 161-169.

  39. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplantation 2011; 46: 1283-1295.

  40. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003; 9: 657-666.

  41. Duncan CN, Buonanno MR, Barry EV, Myers K, Peritz D, Lehmann L. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 971-975.

  42. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005; 36: 135-138.

  43. Smith EP, Sniecinski I, Dagis AC, Parker PM, Snyder DS, Stein AS, et al. Extracorporeal photo-chemotherapy for treatment of drug-resistant graft-vs host disease. Biol Blood Marrow Transplant 1998; 4: 27-37.

  44. Garban F, Drillat P, Makowski C, Jacob MC, Richard MJ, Favrot M, et al. Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Haematologica 2005; 90: 1096- 1101.

  45. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, et al. Extracorporeal photoche-motherapy for the treatment of steroid-resistant chronic GVHD. Blood 2006; 107: 3074- 3080.

  46. Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, et al. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci 2004; 30: 185-187.

  47. Oyan B, Koc Y, Emri S, Kansu E. Improvement of chronic pulmonary graft-vs-host disease manifesting as bronchiolitis obliterans organizing pneumonia following extracorporeal photopheresis. Med Oncol 2006; 23: 125-129.

  48. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant 2006; 12(1 Suppl 2): 37-40.

  49. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant 1999;23: 881-887.

  50. Lucid CE, Savani BN, Engelhardt BG, Shah P, Clifton C, Greenhut SL, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo- SCT. Bone Marrow Transplant 2011; 46: 426-429.

  51. Groetzner J, Wittwer T, Kaczmarek I, Ueberfuhr P, Strauch J, Nagib R, et al. Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation. Transplantation 2006; 81: 355-360.

  52. Hernández RL, Gil PU, Gallo CG, de Pablo Gafas A, Hernandez MC, Alvarez MJ. Rapamycin in lung transplantation. Transplant Proc 2005; 37: 3999-4000.

  53. Snell GI, Valentine VG, Vitulo P, Glanville AR, McGiffin DC, Loyd JE, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant 2006; 6: 169-177.

  54. Borro JM, Bravo C, Sole A, Usetti P, Zurbano F, Lama R, et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. Transplant Proc 2007; 39: 2416-2419.

  55. CelikMR, Lederer DJ, Wilt J, Eser D, Bacchetta M, D’Ovidio F, et al. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study. J Heart Lung Transplant 2009; 28: 697-703.

  56. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005; 25: 490-493.

  57. Fullmer JJ, Fan LL, Dishop MK, Rodgers C, Krance R. Successful treatment of bronchiolitis obliterans in a bone marrow transplant patient with tumor necrosis factor-alpha blockade. Pediatrics 2005; 116: 767-770.

  58. Tun HW, Wallace KH, Grinton SF, Khoor A, Burger CD. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transplant Proc 2005; 37: 4492-4496.

  59. Majhail NS, Schiffer CA, Weisdorf DJ. Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 789-791.

  60. Svendsen UG, Aggestrup S, Heilmann C, Jacobsen N, Koch C, Larsen B, et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur Respir J 1995; 8: 334-337.

  61. Heath JA, Kurland G, Spray TL, Kernan NA, Small TN, Brochstein JA, et al. Lung transplantation after allogeneic marrow transplantation in pediatric patients: the Memorial Sloan-Kettering experience. Transplantation 2001; 72: 1986- 1990.

  62. Rabitsch W, Deviatko E, Keil F, Herold C, Dekan G, Greinix HT, et al. Successful lung transplant-tation for bronchiolitis obliterans after allogeneic marrow transplantation. Transplantation 2001; 71: 1341-1343.

  63. Calhoon JH, Levine S, Anzueto A, Bryan CL, Trinkle JK. Lung transplantation in a patient with a prior bone marrow transplant. Chest 1992; 102: 948.

  64. Boas SR, Noyes BE, Kurland G, Armitage J, Orenstein D. Pediatric lung transplantation for graft-versus-host disease following bone marrow transplantation. Chest 1994; 105: 1584-1586.

  65. Sano Y, Date H, Nagahiro I, Aoe M, Shimizu N. Living donor lobar lung transplantation for bronchiolitis obliterans after bone marrow transplantation. Ann Thorac Surg 2005; 79: 1051-1052.

  66. Or R, Gesundheit B, Resnick I, Bitan M, Avraham A, Avgil M, et al Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007; 83:577-581.

  67. Norman BC, Jacobsohn D, Williams KM, Au B, Au MA, Lee SJ, et al. Fluticasone, azithromycin, and montelukast (FAM) therapy in reducing steroid exposure in bronchiolitis obliterans syndrome after allogenic hematopoetic stem cell transplant (HCT)-a case series of 8 patients. Biol Blood Marrow Transplant 2010;16:S308.




2020     |     www.medigraphic.com